mProX™ Human HAVCR2 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The application of HAVCR2 (also known as TIM-3) has been studied in various contexts. In one study, HAVCR2 was found to be one of the ferroptosis-related long non-coding RNAs (FRLncs) that can influence the prognosis and immune microenvironment in osteosarcoma (OS). The study identified seven FRLncs, including HAVCR2, that could serve as potential prognostic markers and influence factors of the immune microenvironment in OS. Another study investigated the potential impact of HAVCR2 on the tumor microenvironment (TME) in pancreatic cancer. The study found that S100P, a member of the S100 protein family, was associated with an immunosuppressive microenvironment in pancreatic cancer and strongly correlated with HAVCR2 expression. Additionally, HAVCR2 was identified as one of the immune checkpoint-related genes linked to OS prognosis. In colorectal cancer, HAVCR2 was found to be associated with the immunological microenvironment, drug sensitivity, and ferroptosis inhibition. The study identified TIMP1 as a valuable biomarker for colorectal cancer and revealed its positive correlation with HAVCR2 expression. Furthermore, HAVCR2 blockade in diffuse intrinsic pontine glioma (DIPG) models promoted tumor regression and antitumor immune memory. The study demonstrated that inhibition of HAVCR2 in DIPG prolonged survival and produced long-term survivors free of disease that harbored immune memory. These findings suggest that HAVCR2 has potential applications in prognostic markers, immunosuppressive microenvironment, drug sensitivity, and antitumor immune response.